CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process
This article was originally published in The Gray Sheet
Executive Summary
FDA seeks to underscore its commitment to help innovative new medical devices get to market more quickly with a report unveiled May 22
You may also be interested in...
Imaging Is Key To Product Development In Critical Path Opportunities List
Imaging techniques hold "vast potential" to help speed the development of new medical products, FDA says in the latest report on its Critical Path initiative
MDUFMA II Should Address Pre-IDE Process, Cycle Goals – Stakeholders
FDA should work to improve the process by which companies and the agency negotiate clinical trial designs, several participants argued at the third annual MDUFMA stakeholder meeting Nov. 17
McClellan’s FDA Legacy? Decisive Role In Product Development Priorities
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress